Oncopharmpod
Loong TFRs In CML, A Lack Of Agility, & CHEKCMATE 816
- Author: Vários
- Narrator: Vários
- Publisher: Podcast
- Duration: 0:21:38
- More information
Informações:
Synopsis
Treatment-free remission (TFR) rates in CML of close to 80% have recently been described (https://doi.org/10.1002/ajh.26550). The AGILE study. If you can't say anything nice. Checking back in on CHECKMATE 816 (neoadjuvant Nico-Chemo in NSCLC) and Keynote-177 (pembrolizumab in MSI-H/dMMR colorectal cancer).
